Nordea Investment Management AB Has $1.74 Million Holdings in Hologic, Inc. $HOLX

Nordea Investment Management AB trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 99.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,325 shares of the medical equipment provider’s stock after selling 2,809,275 shares during the quarter. Nordea Investment Management AB’s holdings in Hologic were worth $1,739,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Winnow Wealth LLC acquired a new position in shares of Hologic during the 3rd quarter worth approximately $26,000. Root Financial Partners LLC bought a new position in shares of Hologic during the third quarter worth approximately $27,000. SJS Investment Consulting Inc. raised its position in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 168.5% in the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 310 shares during the period. Finally, Loomis Sayles & Co. L P bought a new stake in shares of Hologic in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.0%

Shares of HOLX opened at $75.67 on Friday. The firm has a 50 day simple moving average of $75.22 and a two-hundred day simple moving average of $73.29. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.75. The company has a market cap of $16.89 billion, a P/E ratio of 31.53, a P/E/G ratio of 2.25 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business posted $0.87 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on HOLX. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and reduced their price target for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.